Open Access Full Text Article

## CORRIGENDUM

## Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People's Republic of China [Corrigendum]

Li J, Ren HY, Zhang J, et al. *Comparative Effectiveness Research*. 2017;7:1–9

On page 8, Acknowledgments section, "The abstract of this study was presented at the ISPOR 18<sup>th</sup> Annual European Congress as a poster presentation with interim findings. The poster's abstract was published in "Poster Abstracts" in Value In Health 2015 November issue.<sup>21</sup>" should have been "The abstract of this study was presented at the ISPOR 18<sup>th</sup> Annual European Congress as a poster presentation with interim findings. The poster's abstract was published in "Poster Abstracts" in Value In Health 2015 November issue.<sup>21</sup> The authors thank Dr. Liheng Ma from China Pfizer Medical, who provided medical insight in the study design phase and helped to secure the research funding. This work would not have been possible without such support."

## Comparative Effectiveness Research

## **Dove**press

I

Publish your work in this journal

Comparative Effectiveness Research is an international, peer reviewed open access journal focusing on comparative effectiveness of health care including preventative health care strategies, diagnostic strategies, diagnostic technology, medical devices, drugs, medical technology, health systems and organization. The manuscript management system

health system. Visit http://www.dovepress.com/testimonials.php to read real regies, quotes from published authors.

is completely online and includes a very quick and fair peer-review

Submit your manuscript here: https://www.dovepress.com/comparative-effectiveness-research-journal

submit your manuscript | www.dovepress.com
Dovepress

http://dx.doi.org/10.2147/CER.S151220

Comparative Effectiveness Research 2018:8 I

Construction of the second sec